Record YoY growth masks weakening Q2 momentum; capex execution key
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit Q2 numbers as stated; prior capex/margin targets maintained. Debottlenecking timeline slipped from committed Q3 to 'planning stage'.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 delivered strong 42% YoY revenue growth (₹459 Cr) and 52% YoY PAT (₹81 Cr), with EBITDA margin steady at 25.8%. However, sequential PAT growth slowed sharply to 2.7% (vs 52% YoY), signaling demand/margin pressure within Q2 itself. Management's shift to refusing forward guidance ('good growth' vs prior 40%+ aspiration) and delay of debottlenecking from Q3 FY27 to 'planning stage' suggest caution entering H2. Capex execution and freight cost normalization are key catalysts.
₹458.9 Cr
Revenue · +41.9% YoY₹80.8 Cr
Reported PAT · +51.8% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 revenue INR459 Cr, up 41.9% YoY from INR323 Cr
METDelivered ₹458.9 Cr, YoY 41.9% — verbatim match
Q2 PAT INR81 Cr, grew 51.8% YoY from INR53 Cr
METDelivered ₹80.8 Cr, YoY 51.8% — exact match
EBITDA margin 25.8%, grew 34.4% YoY; PAT margin 17.6%
METDelivered OPM 25.8%, NPM 17.3% — margin levels consistent
Plant utilization ~85% on 47,500-ton capacity
METCorroborated by delivered margin/volume metrics; no contrary evidence
QoQ PAT growth modest due to inventory timing, freight pressure
METDelivered ₹80.8 Cr (Q2) vs ~₹78.6 Cr implied Q1 = 2.7% QoQ, confirms thesis
Earnings quality
What changed since the last call
Debottlenecking timeline softened
DowngradePrior Q1 FY27 call: Q3 FY27 target. Current: 'Under planning, will update in Q3'. Design phase ongoing; capex ₹70–75 Cr done. Effectively delayed.
Forward growth guidance now directional, not quantified
DowngradePrior: implicit 40%+ growth trajectory. Current: Mgmt explicitly refused to quantify FY27 growth %, stating 'good growth' only. Analyst Utkarsh pressed for 40%/30%/20%; mgmt declined, citing 'longer-term vision'.
Value-added mix (CBE + stearin) improving
UpgradeNow 70–75% (from prior 65–70%). Targeting 70–80% going forward. Higher margin contribution per unit.
Freight cost headwind disclosed explicitly
NeutralQ2 impact: ₹480 bps. Global logistics (Red Sea, shipping costs) driver, not raw material inflation. Mgmt expects normalization.
The Q&A
Analysts pressed hard on three fronts: (1) Raw material cost vs freight (Nitin, BoI Mutual Fund) — mgmt held firm, clarified freight driver. (2) Cocoa price linkage to CBE/stearin realization (Vanshika, Task) — mgmt deflected, saying no direct link due to different processes. (3) Forward growth quantification (Utkarsh, Eiko Quantum) — mgmt refused, defended 'long-term vision' over quarterly targets. Overall: mgmt confident but defensive on near-term details and forward numbers.
Cost drivers: raw material vs freight — Nitin, Bank of India Mutual Fund
AnsweredFreight cost is the primary driver, not raw material itself. We import from West African regions now; shipping/logistics inflation (Red Sea, global routes) causing headwind. Largely external macro factor.
Project status & inventory drivers — Tanay Jain, Ambit Capital
AnsweredBurkina Faso on track, designing & engineering phase. LATAM progressing, shipments booked gradually. Inventory shea nuts seasonal; we started importing from West Africa region. Will normalize H2.
Volume vs realization breakdown — Dipali, Jefferies
Answered85% volume growth, 10–15% price realization. Capex to date: ₹70–75 Cr. Debottlenecking under planning for Q3 only. Design engineer in critical phase.
Cocoa price linkage to product realization — Vanshika Gupta, Task Investments
PartialNo direct linkage. CBE manufacturing is different process; raw materials/processes different from cocoa butter. Contracts renewing; prices stable in current mode. No direct impact.
Shea procurement cost YoY increase — Praveen Jayaraman, Avendus
PartialFreight has increased. We import shea from West African countries. Price inflation impact already in books. Can share exact percentage offline with advisors.
ROCE from capex, volume growth rate — Koushik Mohan, Trinetra Asset Managers
PartialH1 strong base; H2 to benefit from debottlenecking and ramp-up. Expect 85–90% utilization over 2–3 years. Can't quantify exact growth percentage now.
CBE/stearin contribution peak range — Tushar Khandelwal, Nexus Equity
AnsweredCurrently 70–75% contribution. Comfortable band 70–80%. Solvent fractionation plant under planning and engineering stage. Complex projects; will update when materialized.
FY27 capacity utilization, new capacity timeline — Nipun Sharma, VLS Finance
AnsweredExisting capacity 85% currently. New capacity from Q3 FY28 starting 40–50% utilization, reaching 85–90% over 2–3 years. Gradual ramp as commissioned.
Customer demand, slowdown or deferrals — Mahima Gidwani, PhillipCapital
AnsweredNo slowdown currently. Capacities fully booked for next kind of year. No deferrals observed. Demands are very healthy; adding new customers from new geographies.
Fractionation mix, margin guidance — Yogeeta Rathod, Aditya Birla Capital
AnsweredFractionation 75%, others 25% of volumes. No numeric margin guidance, but 25–27% band comfortable for us. Modest quarter-to-quarter movements expected due to macro.
Sustainable growth with existing capacity — Onkar, Shree Investment
PartialGood headroom through FY27–28. New capacity from FY28 onwards. Believe leverage will improve margin. Currently within comfortable 25–27% EBITDA band.
Capex complexity and timeline transparency — Mayur Parkeria, Scripbox Wealth Managers
AnsweredLearning from first plant (15K tons), applying to second (25K). Experienced teams. Will keep updating if changes; currently on track with priorities.
Capex commissioning timeline, revenue contribution — Shrenik Mehta, IndoAlps
Partial₹70–75 Cr invested to date. Targeting Q3–Q4 FY28 for commissioning. Will contribute gradually from Q29 onwards as capacity scales.
Inventory pickup drivers — Aditya Sharma, Shikhara Investment Management
AnsweredQ4 FY26 had seasonal sal/mango inventory. Q2 FY27 includes shea nuts bought earlier from West African regions. Early procurement aligned our sourcing. Will normalize Q3–Q4.
Growth rate maintenance with new capacity — Utkarsh Somaiya, Eiko Quantum Solutions
DodgedIt is not about hitting specific percentage. It is longer-term vision. Capex, mix, fundamentals remain intact. Will update on ups and downs in business.
Guidance
FY27 growth expected 'healthy' (not quantified)
MediumManagement explicitly refused to quantify growth %. Analyst Utkarsh asked for 40%/30%/20% targets; mgmt deflected, citing 'longer-term vision'. Prior implicit assumption was 40%+ based on FY26 trajectory; now softened to directional 'good growth'.
EBITDA margin target 25–27% maintained
HighQ2 delivered 25.8%. Mgmt expects modest quarter-to-quarter movements due to macroeconomic factors (freight costs, product mix). Band reflects stable operating performance.
FY27 capex ₹225–250 Cr tracking on schedule
High₹70–75 Cr invested in H1; expect more in H2 FY27 and FY28. Capex projects (Burkina Faso, fractionation plants) targeting Q3 FY28 commissioning; design & engineering phases ongoing.
Risks the call surfaced
Freight cost volatility
MediumRed Sea shipping disruptions and global freight inflation driving ₹480 bps cost pressure in Q2. Externally driven factor, partially hedged via volume and price realization gains (10–15%). Structural margin impact until global logistics normalize.
Capex project execution & timeline risk
MediumBurkina Faso refinery and fractionation plants in 'planning/engineering' stage, not committed timelines. 4,500 MTPA debottlenecking moved from Q3 FY27 (prior Q1 guidance) to 'under planning'. Further delays would compress FY28 growth targets.
Raw material sourcing concentration & geopolitical risk
MediumExpanded sourcing from West Africa (shea nuts, butters) for specialty fats portfolio. Burkina Faso project introduces sovereign and regulatory risk (recent coups, political instability). Concentration risk in one African region for critical inputs.
Sequential demand deceleration
MediumQoQ PAT growth slowed to 2.7% in Q2 (vs 51.8% YoY), suggesting Q1 was stronger or Q2 faced margin/volume headwinds. Contradicts bullish 'full order book' narrative from management. Potential early signal of macro slowdown in key customer markets.
New market entry execution risk
LowLATAM facility ramp-up, West Africa sourcing expansion, new geographic customer acquisition. Scaling operations in unfamiliar markets; requires operational discipline, local partnerships, regulatory navigation.
Management
Score 7/10. Mostly transparent on challenges (freight inflation, inventory timing, project delays). Evasive on forward growth guidance; explicitly refused to quantify FY27–FY28 revenue targets despite 42% YoY growth. Defensive tone on new capex timelines and execution. Leadership reorganization (Ashish Saraf as President, Vinita as President Business Excellence) signals maturation but no crisis. Hit Q2 numbers delivered (₹459 Cr revenue, ₹81 Cr PAT) as stated in call. Capex tracking prior guidance (₹70–75 Cr done, ₹225–250 Cr FY27 target on track). Debottlenecking timeline softened from Q3 FY27 (prior call) to 'planning stage' — soft miss on prior commitment.
1 · Q3 FY27
Debottlenecking commissioning (4.5K MTPA), inventory normalization expected
2 · Q3 FY28
Burkina Faso refinery/fractionation plant commissioning; 3-year payback target
3 · FY28–29
New capacity ramps to 85%–90% utilization; margin uplift from operating leverage
Capex execution and freight cost normalization are key catalysts.
Informational and educational content only. Not investment advice.